beclomethasone dipropionate - Profile

What are the generic sources for beclomethasone dipropionate and what is the scope of freedom to operate?

Beclomethasone dipropionate is the generic ingredient in twelve branded drugs marketed by Amneal Ireland Ltd, Glaxosmithkline, Teva Branded Pharm, Norton Waterford, and Schering, and is included in twelve NDAs. There are twenty patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Beclomethasone dipropionate has three hundred and twenty-five patent family members in thirty-two countries.

There is one tentative approval for this compound.

Summary for beclomethasone dipropionate

International Patents:	325
US Patents:	20
Tradenames:	12
Applicants:	5
NDAs:	12
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for beclomethasone dipropionate

Generic filers with tentative approvals for BECLOMETHASONE DIPROPIONATE

Applicant	Application No.	Strength	Dosage Form
		0.04MG/INH	AEROSOL, METERED;INHALATION
		0.08MG/INH	AEROSOL, METERED;INHALATION

The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.

Paragraph IV (Patent) Challenges for BECLOMETHASONE DIPROPIONATE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
QVAR REDIHALER	Inhalation Aerosol	beclomethasone dipropionate	80 mcg/actuation	207921	1	2024-07-31
QVAR REDIHALER	Inhalation Aerosol	beclomethasone dipropionate	40 mcg/actuation	207921	1	2023-10-30
QVAR 80	Inhalation Aerosol	beclomethasone dipropionate	40 mcg/actuation and 80 mcg/actuation	020911	1	2020-01-10

US Patents and Regulatory Information for beclomethasone dipropionate

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Amneal Ireland Ltd	BECLOMETHASONE DIPROPIONATE	beclomethasone dipropionate	AEROSOL, METERED;INHALATION	213811-001	Dec 16, 2025		RX	No	Yes
Amneal Ireland Ltd	BECLOMETHASONE DIPROPIONATE	beclomethasone dipropionate	AEROSOL, METERED;INHALATION	213811-002	Dec 16, 2025		RX	No	Yes
Glaxosmithkline	BECLOVENT	beclomethasone dipropionate	AEROSOL, METERED;INHALATION	018153-001	Approved Prior to Jan 1, 1982		DISCN	No	No
Teva Branded Pharm	QVAR 40	beclomethasone dipropionate	AEROSOL, METERED;INHALATION	020911-002	Sep 15, 2000		DISCN	Yes	No			Y		Y
Teva Branded Pharm	QVAR 40	beclomethasone dipropionate	AEROSOL, METERED;INHALATION	020911-002	Sep 15, 2000		DISCN	Yes	No			Y		Y

Expired US Patents for beclomethasone dipropionate

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Teva Branded Pharm	QVAR 40	beclomethasone dipropionate	AEROSOL, METERED;INHALATION	020911-002	Sep 15, 2000
Teva Branded Pharm	QVAR 80	beclomethasone dipropionate	AEROSOL, METERED;INHALATION	020911-001	Sep 15, 2000
Teva Branded Pharm	QVAR 40	beclomethasone dipropionate	AEROSOL, METERED;INHALATION	020911-002	Sep 15, 2000
Teva Branded Pharm	QVAR 40	beclomethasone dipropionate	AEROSOL, METERED;INHALATION	020911-002	Sep 15, 2000
Glaxosmithkline	BECLOVENT	beclomethasone dipropionate	AEROSOL, METERED;INHALATION	018153-001	Approved Prior to Jan 1, 1982

International Patents for beclomethasone dipropionate

Country	Patent Number	Title	Estimated Expiration
South Korea	20130103824
Israel	247394
Japan	6273242
Spain	2404818
Japan	5820007

Investment Scenario, Market Dynamics, and Financial Trajectory for Beclomethasone Dipropionate

Last updated: February 3, 2026

Executive Summary

Beclomethasone dipropionate (BDP) is a potent inhaled corticosteroid primarily prescribed for asthma, allergic rhinitis, and other inflammatory respiratory conditions. With an established safety profile, expanding indications, and evolving treatment guidelines, BDP presents promising investment opportunities. The global inhaled corticosteroids (ICS) market is projected to grow at a CAGR of approximately 4.3% from 2023 to 2028, driven by rising respiratory disorders prevalence, increased healthcare access, and technological advancements in drug delivery systems.

This report analyzes BDP’s current market position, competitive landscape, regulatory environment, and future financial trajectory to inform strategic investment decisions.

---

1. Market Overview and Defining Parameters

Global Market Size & Growth (2023-2028)

Parameter	2023 Estimate	2028 Projection	CAGR (2023-2028)
Global ICS Market	~$17.2 billion	~$21.8 billion	4.3%
Beclomethasone Market Share	~12% (estimated)	Maintains steady share	--

Source: Grand View Research, 2023; ReportsResearch.com, 2022.

Main Indications and Usage

Indication	Market Penetration (%)	Growth Drivers
Asthma	~60%	Rising asthma prevalence, improved inhaler devices
Allergic Rhinitis	~25%	Increased allergy awareness, OTC availability
COPD (Chronic Obstructive Pulmonary Disease)	~10%	Emerging off-label uses for airway inflammation
Other (e.g., dermatitis, conjunctivitis)	~5%	New formulations during clinical trials

---

2. Key Market Dynamics Influencing BDP Investment

a. Epidemiological Trends

• Global Respiratory Disease Burden:
  • WHO estimates over 339 million asthma cases globally (2023).
  • Asthma incidence rising due to urbanization, pollution, and smoking habits.
  • COPD expected to surpass asthma in mortality rates by 2030.[1]

b. Competitive Landscape

Company	Product Portfolio	Market Share (%)	Key Differentiators
Teva Pharmaceuticals	Qvar (allergen-free steroid)	~35%	Established inhaler technology
AstraZeneca	Pulmicort (budesonide)	~30%	Extensive R&D, global reach
GlaxoSmithKline (GSK)	Fluticasone-based products	~25%	Market penetration, diverse delivery options
Others	Various generics & OTC forms	~10%	Competitive pricing

Note: BDP is marketed under various generic and branded names (e.g., Qvar, Beclovent).

c. Regulatory & Policy Environment

• Approvals & Reimbursement:
  • Widely approved in North America, Europe, Asia.
  • Increasing reimbursement coverage boosts adoption.
• Biosimilar & Generic Competition:
  • Patent expirations expected between 2025-2028.
  • Entry of biosimilars could influence prices and margins.

d. Technological Innovations

• Inhaler Devices & Formulations:
  • Growth in dry powder inhalers (DPI) and breath-actuated devices.
  • Smart inhalers with IoT integration enhance compliance and monitoring.
• Nano-formulations & Novel Delivery:
  • Potential to increase bioavailability and reduce side effects.
  • Ongoing clinical trials could expand BDP's application scope.

---

3. Financial Trajectory & Investment Outlook

a. Revenue Projections (2023-2028)

Year	Estimated Revenue (USD Million)	Assumptions
2023	~$250	Current market share + growth factors
2024	~$275	Launch of new formulations
2025	~$300	Patent expiration for some competitors
2026	~$330	Entry of biosimilars; pricing adjustments
2027	~$370	Expansion into emerging markets
2028	~$420	Market maturation; increased adoption

b. Cost Structure Considerations

• R&D investments underpin innovation; estimates range from $50–$80 million annually for new formulations.
• Manufacturing costs decline with scale; estimated gross margins of 60-65% for branded BDP products.
• Regulatory compliance and patent strategy influence margins and market entry barriers.

c. Profitability Analysis

• Gross Profit (2028 projected):
  • Revenue: ~$420M
  • Cost of Goods Sold (COGS): ~$150M (assuming 35% COGS)
  • Gross Profit: ~$270M
• Operating Expenses:
  • R&D: ~$60M
  • Marketing & Distribution: ~$20M
• Net Profit Estimate:
  • ~$190M (approximate 45% profit margin)

d. Investment Risks & Opportunities

Risk Factors	Impact	Mitigation Strategies
Patent expirations	Price competitiveness, margins decline	Patent extension, R&D for new formulations
Regulatory delays	Market entry delays	Early engagement, robust regulatory strategy
Competitive biosimilars	Price erosion, market share loss	Differentiation, patent prosecutions
Manufacturing disruptions	Supply chain impacts	Diversified suppliers, inventory buffers

---

4. Comparative Analysis with Competitors

Aspect	Beclomethasone Dipropionate	Budesonide (Pulmicort)	Fluticasone (Flovent)	Mometasone (Nasonex)
Market Adoption Rate	Moderate	High	Very High	Moderate
Side Effect Profile	Mild	Mild	Mild to moderate	Mild
Cost Effectiveness	High	Moderate	Moderate	High
Delivery Innovations	AeroChamber, innovative DPIs	Advanced inhalers	Smart inhalers	Limited

Key Takeaway: BDP's affordability and safety profile combined with innovative delivery devices confer a strategic advantage, especially in emerging markets.

---

5. Future Market Drivers & Strategic Recommendations

Factors Accelerating BDP Market Growth

• Increasing prevalence of asthma and allergic diseases.
• Patient preference for inhaled therapies with fewer side effects.
• Integration of smart inhaler technology to improve compliance.
• Expansion into developing markets with large unmet needs.

Strategic Investment Recommendations

• R&D Focus: Prioritize formulations with enhanced bioavailability and reduced dosing frequency.
• Market Expansion: Target markets with high respiratory disease burdens (India, Southeast Asia).
• Partnerships: Collaborate with device manufacturers to accelerate delivery system innovation.
• Intellectual Property: Engage in patent filings and legal protections to extend market exclusivity.
• Regulatory Engagement: Proactively address evolving guidelines, especially concerning biosimilar approvals.

---

Conclusion

Investing in BDP offers a balanced risk-profile with potential for steady revenue growth amid a growing respiratory disease market. The drug's established efficacy, safety, and flexible delivery systems make it suitable for sustained demand. However, future success hinges on innovation, navigating patent expirations, and expanding into emerging markets. Strategic positioning around technological enhancements and regulatory navigation can maximize financial returns.

---

Key Takeaways

• The global ICS market is expected to grow at a CAGR of 4.3% through 2028.
• Patent expirations post-2024 may pressure prices but also create opportunities for generics and biosimilars.
• BDP maintains a competitive edge through safety, affordability, and innovative delivery methods.
• Anticipated revenue for BDP could reach approximately USD 420 million by 2028.
• Strategic investments should prioritize innovation, market expansion, and regulatory efficacy to capitalize on growth opportunities.

---

FAQs

Q1: How does patent expiration influence BDP's market share and profitability?
Patent expirations typically lead to increased generic competition, exerting downward pressure on prices and margins. Companies need to innovate or develop new formulations to sustain market share and profitability.

Q2: What are the key drivers for BDP's growth in emerging markets?
Growing respiratory disease prevalence, increasing healthcare access, government health initiatives, and lower-cost generic options contribute to BDP’s expanding footprint in emerging markets.

Q3: How might technological innovations impact BDP’s market performance?
Advancements such as smart inhalers and nano-formulations can improve drug efficacy, patient compliance, and healthcare provider preference—driving market expansion.

Q4: Are there any clinical or regulatory barriers to BDP's future growth?
Potential barriers include delays in regulatory approvals for new formulations, safety concerns with biosimilars, and reimbursement limitations. Proactive engagement and robust clinical data are essential.

Q5: How does BDP compare to other ICS agents in terms of cost-effectiveness?
BDP generally offers a cost-effective profile due to its lower manufacturing costs, widespread generic availability, and favorable safety profile, making it attractive in price-sensitive markets.

---

References

1. World Health Organization. "Global Surveillance, Prevention and Control of Chronic Respiratory Diseases." 2022.
2. Grand View Research. "Inhalation Drugs Market Size, Share & Trends Analysis." 2023.
3. ReportsResearch.com. "Respiratory Diseases & Inhaled Corticosteroids Market Report." 2022.
4. AstraZeneca Investor Relations. "Market Data and Product Portfolio." 2022.
5. U.S. FDA. "Regulatory Framework for Inhaled Products." 2023.